Dr. Emilia Falcone is an assistant clinical professor in the Department of Medicine at Université de Montréal. Infectious diseases specialist at Centre Hospitalier de l’Université de Montréal (CHUM), she holds a Canada Research Chair in the Role of the Microbiome in Primary Immunodeficiency. She is also the director of the microbiome and mucosal defense research unit at the Montreal Clinical Research Institute (IRCM) and director of the IRCM Post-COVID-19 research clinic

• Falcone studied medicine at McGill University in Montreal and obtained a specialization in internal medicine at Tufts Medical Center in Boston. She then spent 8 years at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). During this time, she completed a fellowship in Infectious Diseases while also obtaining a Ph.D. at the University of Cambridge as an NIH-Oxford-Cambridge scholar. She then became an Assistant Clinical Investigator at the NIH as a recipient of the NIAID Transition Program in Clinical Research award and developed a unique research program focused on the role of the microbiota in the modulation of inflammatory complications in patients with inborn errors of immunity. Dr. Falcone was recruited to the IRCM at the end of 2018.
• During the COVID-19 pandemic, Dr. Falcone established the IRCM Post-COVID-19 (IPCO) research clinic, the first clinic of its kind in Montreal. The IPCO research clinic integrates the clinical evaluation of post-acute COVID-19 sequelae with a research protocol (clinicaltrials.gov; NCT04736732) and biobank aimed at understanding the pathogenesis of the post-COVID-19 condition in order to identify new therapies. Dr. Falcone is also a member of the Biobanque Québécoise de la COVID-19 (BQC19) steering committee.